IN2014KN01713A - - Google Patents

Info

Publication number
IN2014KN01713A
IN2014KN01713A IN1713KON2014A IN2014KN01713A IN 2014KN01713 A IN2014KN01713 A IN 2014KN01713A IN 1713KON2014 A IN1713KON2014 A IN 1713KON2014A IN 2014KN01713 A IN2014KN01713 A IN 2014KN01713A
Authority
IN
India
Prior art keywords
antibody
cancer
amino acid
acid sequence
seq
Prior art date
Application number
Inventor
Shinichi Kobayashi
Fumiyoshi Okano
Takanori Saito
Original Assignee
Toray Industries
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toray Industries filed Critical Toray Industries
Publication of IN2014KN01713A publication Critical patent/IN2014KN01713A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention discloses an antibody that targets a cancer antigen protein expressed specifically on the surface of cancer cells and the application of the antibody in a treatment and/or preventative agent for said cancer. Specifically disclosed are: an antibody or a fragment thereof said antibody being immunologically reactive with a partial polypeptide of CAPRIN 1 comprising the amino acid sequence represented by SEQ ID NO: 5 or an amino acid sequence having 80% or more sequence identity to the amino acid sequence represented by SEQ ID NO: 5; and a pharmaceutical composition for the treatment and/or prevention of cancer said pharmaceutical composition being characterized by containing as an active ingredient the antibody or a fragment thereof.
IN1713KON2014 2012-02-21 2013-02-21 IN2014KN01713A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2012035484 2012-02-21
PCT/JP2013/054337 WO2013125636A1 (en) 2012-02-21 2013-02-21 Pharmaceutical composition for treatment and/or prevention of cancer

Publications (1)

Publication Number Publication Date
IN2014KN01713A true IN2014KN01713A (en) 2015-10-23

Family

ID=49005813

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1713KON2014 IN2014KN01713A (en) 2012-02-21 2013-02-21

Country Status (16)

Country Link
US (1) US9273130B2 (en)
EP (1) EP2818482B1 (en)
JP (1) JP6187255B2 (en)
KR (1) KR102009238B1 (en)
CN (1) CN104169303B (en)
AU (1) AU2013223143B2 (en)
CA (1) CA2864864C (en)
DK (1) DK2818482T3 (en)
ES (1) ES2739612T3 (en)
HU (1) HUE044611T2 (en)
IN (1) IN2014KN01713A (en)
MX (1) MX360208B (en)
PL (1) PL2818482T3 (en)
PT (1) PT2818482T (en)
RU (1) RU2632645C2 (en)
WO (1) WO2013125636A1 (en)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2322221E (en) 2008-08-05 2014-09-19 Toray Industries Pharmaceutical composition for treatment and prevention of cancer
BRPI0911925B8 (en) 2008-08-05 2024-02-06 Toray Industries Method to detect cancer
KR101805520B1 (en) * 2010-02-04 2017-12-07 도레이 카부시키가이샤 Pharmaceutical composition for treatment and/or prevention of cancer
WO2013018886A1 (en) * 2011-08-04 2013-02-07 東レ株式会社 Pharmaceutical composition for treatment and/or prevention of pancreatic cancer
PT2741085T (en) * 2011-08-04 2017-06-30 Toray Industries Method for detecting pancreatic cancer
EP2818483B1 (en) 2012-02-21 2017-08-02 Toray Industries, Inc. Medicinal composition for treating and/or preventing cancer
CA2869123C (en) 2012-03-30 2021-03-16 Toray Industries, Inc. Pharmaceutical composition comprising anti-caprin-1 antibodies for the treatment of gallbladder cancer
CN104220095B (en) * 2012-03-30 2016-09-07 东丽株式会社 The treatment of liver cancer and/or prophylactic compositions
EP2876446B1 (en) 2012-07-19 2018-12-26 Toray Industries, Inc. Method for detecting cancer
PL2876447T3 (en) 2012-07-19 2020-05-18 Toray Industries, Inc. Method for detecting cancer
US9758591B2 (en) 2012-08-24 2017-09-12 The Regents Of The University Of California Antibodies and vaccines for use in treating ROR1 cancers and inhibiting metastasis
EP3031826B1 (en) 2013-08-09 2018-10-10 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer
US10537633B2 (en) 2016-03-04 2020-01-21 Jn Biosciences Llc Antibodies to TIGIT
MX2018016330A (en) 2016-06-27 2020-02-17 Univ California COMBINATIONS FOR CANCER TREATMENT.
KR102726248B1 (en) 2016-07-07 2024-11-05 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 Antibody adjuvant conjugates
EP3533466A4 (en) 2016-10-28 2020-06-10 Toray Industries, Inc. PHARMACEUTICAL COMPOSITION FOR THE TREATMENT AND / OR PREVENTION OF CANCER
BR112020019935A2 (en) 2018-03-30 2021-01-26 Toray Industries, Inc. medicine for the treatment and / or prevention of cancer, agents that increase the effectiveness of a drug and method of treatment and / or prevention of cancer
CA3130794A1 (en) 2019-03-15 2020-09-24 Bolt Biotherapeutics, Inc. Immunoconjugates targeting her2
CA3142887A1 (en) 2019-06-13 2020-12-17 Bolt Biotherapeutics, Inc. Aminobenzazepine compounds, immunoconjugates, and uses thereof
WO2021067242A1 (en) 2019-09-30 2021-04-08 Bolt Biotherapeutics, Inc. Amide-linked, aminobenzazepine immunoconjugates, and uses thereof
TWI857167B (en) 2019-10-25 2024-10-01 美商博特生物治療公司 Thienoazepine immunoconjugates, and uses thereof
BR112022018161A2 (en) * 2020-03-12 2022-10-25 Toray Industries DRUG FOR THE TREATMENT AND/OR PREVENTION OF CANCER, AGENTS THAT INCREASE THE EFFICACY OF A DRUG AND METHOD FOR THE TREATMENT AND/OR PREVENTION OF CANCER
US20230139178A1 (en) * 2020-03-12 2023-05-04 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
US20230140155A1 (en) 2020-03-12 2023-05-04 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
KR20220152318A (en) 2020-03-12 2022-11-15 도레이 카부시키가이샤 Medicines for the treatment and/or prevention of cancer
BR112022018166A2 (en) 2020-03-12 2022-10-25 Toray Industries DRUG FOR TREATMENT AND/OR PREVENTION OF CANCER, AGENTS THAT INCREASE THE DRUG EFFECTIVENESS OF A PHARMACEUTICAL COMPOSITION AND METHOD FOR TREATMENT AND/OR PREVENTION OF CANCER
CA3176626A1 (en) 2020-05-08 2021-11-11 David Dornan Elastase-substrate, peptide linker immunoconjugates, and uses thereof
CR20220611A (en) 2020-06-02 2023-06-07 Arcus Biosciences Inc ANTI-TIGIT ANTIBODIES
US20230263903A1 (en) 2020-08-13 2023-08-24 Bolt Biotherapeutics, Inc. Pyrazoloazepine immunoconjugates, and uses thereof
MX2023014498A (en) 2021-06-23 2024-01-25 Toray Industries MEDICINE FOR THE TREATMENT AND/OR PREVENTION OF CANCER.
BR112023026992A2 (en) 2021-06-23 2024-03-12 Toray Industries MEDICINE FOR THE TREATMENT AND/OR PREVENTION OF CANCER, AGENTS THAT INCREASE THE EFFECTIVENESS OF THE MEDICINE IN A PHARMACEUTICAL COMPOSITION AND METHOD FOR TREATING AND/OR PREVENTING CANCER
JPWO2023008461A1 (en) 2021-07-27 2023-02-02
CA3227698A1 (en) 2021-07-27 2023-02-02 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
CA3227706A1 (en) 2021-07-27 2023-02-02 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
CA3230737A1 (en) 2021-09-03 2023-03-09 Toray Industries, Inc. Pharmaceutical composition for cancer treatment and/or prevention
WO2023076599A1 (en) 2021-10-29 2023-05-04 Bolt Biotherapeutics, Inc. Tlr agonist immunoconjugates with cysteine-mutant antibodies, and uses thereof
US20250367307A1 (en) 2022-06-30 2025-12-04 Toray Industries, Inc. Pharmaceutical composition for cancer treatment and/or prevention
KR20250052364A (en) 2022-08-24 2025-04-18 도레이 카부시키가이샤 Medicines for the treatment and/or prevention of cancer
JPWO2024043252A1 (en) 2022-08-24 2024-02-29
AU2023329564A1 (en) 2022-08-24 2025-02-27 Toray Industries, Inc. Medicament for treatment and/or prevention of cancer
WO2024048541A1 (en) 2022-08-30 2024-03-07 東レ株式会社 Medicament for treatment and/or prevention of cancer
KR20250054778A (en) 2022-08-30 2025-04-23 도레이 카부시키가이샤 Medicines for the treatment and/or prevention of cancer
KR20250118852A (en) 2022-12-23 2025-08-06 도레이 카부시키가이샤 Medicines for the treatment and/or prevention of cancer
JP2026506037A (en) 2023-02-14 2026-02-20 ボルト バイオセラピューティクス、インコーポレーテッド Azabenzazepine immunoconjugates and uses thereof
WO2024186626A1 (en) 2023-03-03 2024-09-12 Bolt Biotherapeutics, Inc. Aza-bicyclic sting agonist immunoconjugates, and uses thereof
AU2024242849A1 (en) 2023-03-28 2025-09-25 Toray Industries, Inc. Method for detecting cell membrane protein
JPWO2024204685A1 (en) 2023-03-31 2024-10-03
WO2025058000A1 (en) * 2023-09-13 2025-03-20 東レ株式会社 Pharmaceutical composition for treating, preventing and/or diagnosing cancer
WO2026055185A1 (en) 2024-09-04 2026-03-12 Bolt Biotherapeutics, Inc. Sting agonist immunoconjugates and uses thereof

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
KR100261941B1 (en) 1994-07-13 2000-07-15 나가야마 오사무 Reconstituted human antibody against human interleukin-8
US5698396A (en) 1995-06-07 1997-12-16 Ludwig Institute For Cancer Research Method for identifying auto-immunoreactive substances from a subject
FR2761994B1 (en) 1997-04-11 1999-06-18 Centre Nat Rech Scient PREPARATION OF MEMBRANE RECEPTORS FROM EXTRACELLULAR BACULOVIRUSES
AU752730B2 (en) 1998-04-03 2002-09-26 Chugai Seiyaku Kabushiki Kaisha Humanized antibody against human tissue factor (TF) and process for constructing humanized antibody
US20030118599A1 (en) 1999-04-02 2003-06-26 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
KR20010083111A (en) 1998-07-14 2001-08-31 길리스 스티브 Compositions and methods for therapy and diagnosis of prostate cancer
RU2234942C2 (en) 1998-07-14 2004-08-27 Корикса Корпорейшн Tumor polypeptide isolated from prostate and polynucleotide encoding thereof
US6969518B2 (en) 1998-12-28 2005-11-29 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
AU3316600A (en) 1999-02-22 2000-09-21 Torben F. Orntoft Gene expression in bladder tumors
US6444425B1 (en) 1999-04-02 2002-09-03 Corixa Corporation Compounds for therapy and diagnosis of lung cancer and methods for their use
HK1045332A1 (en) 1999-04-02 2002-11-22 Corixa Corporation Compounds for therapy and diagnosis of lung cancer and methods for their use
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
EP1224285A4 (en) 1999-10-29 2004-12-08 Human Genome Sciences Inc 27 human secreted proteins
US20020006404A1 (en) 1999-11-08 2002-01-17 Idec Pharmaceuticals Corporation Treatment of cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
JP2004526401A (en) 2000-03-29 2004-09-02 コリクサ コーポレイション Compositions and methods for treatment and diagnosis of lung cancer
JP3523245B1 (en) 2000-11-30 2004-04-26 メダレックス，インコーポレーテッド Transgenic chromosome-introduced rodents for the production of human antibodies
US7919467B2 (en) 2000-12-04 2011-04-05 Immunotope, Inc. Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
US20040029114A1 (en) 2001-01-24 2004-02-12 Eos Technology, Inc. Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer
RU2306952C2 (en) 2001-01-31 2007-09-27 Байоджен Айдек Инк. Method for treating the cases of malignant tumors containing b-cells with a combination of applications related to antibodies reducing b-cells number and with immunomodulating antibodies
WO2002078524A2 (en) 2001-03-28 2002-10-10 Zycos Inc. Translational profiling
WO2002083070A2 (en) 2001-04-10 2002-10-24 Corixa Corporation Compounds for immunotherapy and diagnosis of colon cancer and methods for their use
WO2002092001A2 (en) 2001-05-11 2002-11-21 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
CN1789416B (en) 2001-05-11 2011-11-16 协和发酵麒麟株式会社 Human artificial chromosome containing human antibody lambda light chain
US20030190640A1 (en) 2001-05-31 2003-10-09 Mary Faris Genes expressed in prostate cancer
US20040142325A1 (en) 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
WO2003072035A2 (en) 2002-02-22 2003-09-04 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US20050003390A1 (en) 2002-05-17 2005-01-06 Axenovich Sergey A. Targets for controlling cellular growth and for diagnostic methods
US20040126379A1 (en) 2002-08-21 2004-07-01 Boehringer Ingelheim International Gmbh Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and chemotherapeutic agents
US20060121029A1 (en) 2002-08-30 2006-06-08 Hiroshi Shiku Method and composition for regulating the activity of regulatory t cells
WO2004047728A2 (en) 2002-11-26 2004-06-10 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
WO2004076682A2 (en) 2003-02-26 2004-09-10 Surromed, Inc. Targets for controlling cellular growth and for diagnostic methods
WO2004097051A2 (en) 2003-04-29 2004-11-11 Wyeth Methods for diagnosing aml and mds differential gene expression
EP2003196A3 (en) 2003-06-09 2009-01-07 The Regents of the University of Michigan Compositions and methods for treating and diagnosing cancer
WO2005007830A2 (en) 2003-07-14 2005-01-27 Mayo Foundation For Medical Education And Research Methods and compositions for diagnosis, staging and prognosis of prostate cancer
US20050032113A1 (en) 2003-07-17 2005-02-10 Mitsubishi Pharma Corporation Membrane protein library for proteome analysis and method for preparing same
EP2361929A1 (en) 2004-01-26 2011-08-31 Debiovision Inc. Neoplasm-specific polypeptides and their use
PT1735348E (en) 2004-03-19 2012-07-24 Imclone Llc Human anti-epidermal growth factor receptor antibody
US7858753B2 (en) 2004-03-30 2010-12-28 Glaxo Group Limited Immunoglobulins
WO2005100998A2 (en) 2004-04-16 2005-10-27 Europroteome Ag Membrane markers for use in cancer diagnosis and therapy
DE102004026135A1 (en) 2004-05-25 2006-01-05 Immatics Biotechnologies Gmbh Tumor-associated peptides binding to MHC molecules
WO2006002378A2 (en) 2004-06-23 2006-01-05 Avalon Pharmaceuticals Determining cancer-linked genes and therapeutic targets using molecular cytogenetic methods
UA94899C2 (en) 2005-01-21 2011-06-25 Дженентек, Инк. Fixed dosing of her antibodies
WO2006089212A2 (en) 2005-02-18 2006-08-24 Children's Medical Center Corporation Cyr61 as a biomarker for diagnosis and prognosis of cancers of epithelial origin
NZ560976A (en) 2005-03-11 2011-06-30 Univ Johns Hopkins Biomarkers for ovarian cancer and endometrial cancer: hepcidin
JP2006316040A (en) 2005-05-13 2006-11-24 Genentech Inc HERCEPTIN® adjuvant therapy
US8014957B2 (en) 2005-12-15 2011-09-06 Fred Hutchinson Cancer Research Center Genes associated with progression and response in chronic myeloid leukemia and uses thereof
WO2007095186A2 (en) 2006-02-14 2007-08-23 Dana-Farber Cancer Institute, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer
US20100015724A1 (en) 2006-08-17 2010-01-21 Peter Hornbeck Lysine acetylation sites
US20080107668A1 (en) 2006-08-30 2008-05-08 Immunotope, Inc. Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
US7615349B2 (en) 2006-09-07 2009-11-10 H. Lee Moffitt Cancer Center And Research Institute, Inc. Melanoma gene signature
WO2008059252A2 (en) 2006-11-15 2008-05-22 Oxford Biomedica (Uk) Limited Methods and composition fro t cell receptors which recognize 5t4 antigen
KR20100083768A (en) 2007-10-25 2010-07-22 도레이 카부시키가이샤 Method for detection of cancer
JP5663834B2 (en) 2008-03-14 2015-02-04 東ソー株式会社 Method for producing recombinant antibody
HUE035184T2 (en) 2008-03-18 2018-05-02 Genentech Inc Combinations of anti-HER2 antibody-drug conjugate and docetaxel
DK2328426T3 (en) * 2008-07-31 2014-12-08 Senomyx Inc COMPOSITIONS INCLUDING SWEET AMPLIFIERS AND PROCEDURES FOR PRODUCING THEREOF
BRPI0911925B8 (en) 2008-08-05 2024-02-06 Toray Industries Method to detect cancer
PT2322221E (en) 2008-08-05 2014-09-19 Toray Industries Pharmaceutical composition for treatment and prevention of cancer
BRPI0912462B1 (en) 2008-08-05 2022-03-22 Toray Industries, Inc Use of an immunity-inducing agent, use of a polypeptide, and use of a recombinant vector
AU2010285265B2 (en) 2009-08-19 2015-05-21 Merck Patent Gmbh Antibodies for the detection of integrin complexes in FFPE material
US8642292B2 (en) 2009-09-22 2014-02-04 Probiogen Ag Process for producing molecules containing specialized glycan structures
RU2418587C1 (en) * 2010-01-21 2011-05-20 Государственное образовательное учреждение высшего профессионального образования "Нижегородская государственная медицинская академия Федерального Агентства по здравоохранению и социальному развитию" (ГОУ ВПО "НижГМА Росздрава") Method of treating malignant brain tumours
PL2532364T3 (en) 2010-02-04 2016-11-30 Pharmaceutical composition comprising anti caprin-1 antibodies for treating and/or preventing cancer
ES2583627T3 (en) 2010-02-04 2016-09-21 Toray Industries, Inc. Pharmaceutical composition for the treatment and / or prevention of cancer
KR101805520B1 (en) 2010-02-04 2017-12-07 도레이 카부시키가이샤 Pharmaceutical composition for treatment and/or prevention of cancer
CA2788716C (en) 2010-02-04 2019-06-18 Toray Industries, Inc. Pharmaceutical composition for treating and/or preventing cancer
BR112012018943A8 (en) 2010-02-04 2017-12-19 Toray Industries medicine and method for treating and / or preventing cancer
US8709418B2 (en) 2010-02-04 2014-04-29 Toray Industries, Inc. Pharmaceutical composition for treating CAPRIN-1 expressing cancer
WO2012005550A2 (en) 2010-07-08 2012-01-12 강원대학교산학협력단 Pharmaceutical composition for treating gallbladder carcinoma, and method for inhibiting growth and metastasis of gallbladder carcinoma and treating gallbladder carcinoma, using same
CN103261224B (en) 2010-07-26 2015-10-07 瑟维尔实验室 Methods and compositions for the treatment of liver cancer
JP2012035484A (en) 2010-08-06 2012-02-23 Tombow Pencil Co Ltd Coating film transfer tool
WO2013018886A1 (en) 2011-08-04 2013-02-07 東レ株式会社 Pharmaceutical composition for treatment and/or prevention of pancreatic cancer
ES2634249T3 (en) 2011-08-04 2017-09-27 Toray Industries, Inc. Pharmaceutical composition for the treatment and / or prophylaxis of cancer
PT2741085T (en) 2011-08-04 2017-06-30 Toray Industries Method for detecting pancreatic cancer
CA2869123C (en) 2012-03-30 2021-03-16 Toray Industries, Inc. Pharmaceutical composition comprising anti-caprin-1 antibodies for the treatment of gallbladder cancer
CN104220095B (en) * 2012-03-30 2016-09-07 东丽株式会社 The treatment of liver cancer and/or prophylactic compositions

Also Published As

Publication number Publication date
KR20140130668A (en) 2014-11-11
EP2818482A1 (en) 2014-12-31
CN104169303B (en) 2018-05-29
AU2013223143B2 (en) 2017-12-21
CN104169303A (en) 2014-11-26
WO2013125636A1 (en) 2013-08-29
EP2818482B1 (en) 2019-05-22
EP2818482A4 (en) 2015-10-07
HUE044611T2 (en) 2019-11-28
CA2864864A1 (en) 2013-08-29
MX360208B (en) 2018-10-24
JP6187255B2 (en) 2017-08-30
AU2013223143A1 (en) 2014-09-11
KR102009238B1 (en) 2019-08-09
CA2864864C (en) 2020-05-12
BR112014021101A2 (en) 2022-03-22
DK2818482T3 (en) 2019-07-15
RU2632645C2 (en) 2017-10-06
ES2739612T3 (en) 2020-02-03
PL2818482T3 (en) 2019-11-29
JPWO2013125636A1 (en) 2015-07-30
US9273130B2 (en) 2016-03-01
PT2818482T (en) 2019-08-06
RU2014138040A (en) 2016-04-10
US20150004171A1 (en) 2015-01-01
MX2014009748A (en) 2014-11-14

Similar Documents

Publication Publication Date Title
IN2014KN01713A (en)
IN2014KN01714A (en)
IN2014KN01716A (en)
IN2014KN01715A (en)
MX2014001375A (en) Pharmaceutical composition for treatment and/or prophylaxis of cancer.
MX2014001372A (en) Pharmaceutical composition for treatment and/or prevention of pancreatic cancer.
MX2012008999A (en) Pharmaceutical composition for treatment and/or prevention of cancer.
MX2012008998A (en) Pharmaceutical composition for treatment and/or prevention of cancer.
MX2012009000A (en) Pharmaceutical composition for treatment and/or prevention of cancer.
MX340016B (en) Pharmaceutical composition for treatment and/or prevention of cancer.
MX360671B (en) Pharmaceutical composition for treatment and/or prevention of cancer.
WO2017009843A3 (en) Compositions, articles of manufacture and methods for treating cancer
NZ713461A (en) Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer
NZ761006A (en) Plasma kallikrein binding proteins and uses thereof in treating hereditary angioedema
MX357965B (en) Pharmaceutical composition for treatment and/or prevention of gall bladder cancer.
NZ705370A (en) Fcγriib-specific fc region variant
MY167232A (en) Polypeptides binding to human complement c5
IN2014DN09963A (en)
MX369195B (en) Mutant fragments of ospa and methods and uses relating thereto.
GB201118201D0 (en) Novel peptides
AR120721A2 (en) PEPTIDES AND COMPOSITIONS FOR THE TREATMENT OF JOINT DAMAGE
EA201790341A1 (en) ANTI-CK8 ANTIBODIES FOR USE IN TREATMENT OF CANCER
EA201590601A1 (en) APPLICATION OF PEDF-DERIVED POLYPEPTIDES FOR THE TREATMENT OF OSTEOARTHRITIS
WO2014039074A3 (en) Therapeutic compositions and related methods
MX2015002279A (en) Synthetic pntx(19) peptide, pharmaceutical compositions and use.